Drugs / LY3381916
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03343613 | Nov 2017 → Feb 2020 | non-small cell lung carcinoma, renal cell carcinoma, triple-negative breast carcinoma | Eli Lilly and Company | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3381916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03343613 ↗ |
| Action | Inhibit | “IDO-1 inhibitor administered orally” NCT03343613 ↗ |
| Modality | Small molecule | — CHEMBL4778760 ↗ |
| Route | Oral | “LY3381916 administered orally.” NCT03343613 ↗ |